Zynerba Pharmaceuticals
Devon
About Zynerba Pharmaceuticals
Zynerba Pharmaceuticals is dedicated to the development of innovative transdermal cannabinoid treatments for patients with high unmet medical needs using modern drug delivery technology and appropriate regulatory pathways. Zynerba is developing two therapeutic candidates based on proprietary transdermal technologies that, if successfully developed, may allow sustained, consistent and controlled delivery of therapeutic levels of cannabinoids. Transdermal delivery reduces adverse effects associated with oral dosing. ZYN001 will be studied in fibromyalgia, neuropathic pain and chronic cancer pain utilizing a synthetically manufactured prodrug of THC in a transdermal patch to deliver THC through the skin and into the bloodstream. Zynerba expects to initiate ZYN001 Phase 1 clinical studies in 2Q 2015. ZYN002 will be studied in epilepsy and rheumatoid arthritis, utilizing a proprietary gel to deliver synthetically manufactured cannabidiol (CBD), a non-psychotropic cannabinoid, through the skin and into the bloodstream. Zynerba expects to initiate ZYN002 Phase 1 clinical studies in 3Q 2015. Learn more at www.zynerba.com and follow the company on Twitter at @ZynerbaPharma.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 1 – 10
- Estimated revenue: Less than $1M
- Total funding: $13.0M
- Funding stage: M&A
- Last round: Series Unknown (Oct 2014)
- Ticker: nasdaq:ZYNE
- Website: zynerba.com
- Phone: +1 484 581 7505
Industries & Categories
Biotechnology, Developer Tools, Health Care, Pharmaceutical, Product Design
Social Profiles
Canonical: https://fsome.com/organization/zynerba-pharmaceuticals-1407671 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.